QRON Stock Analysis
QR
Uncovered
Qrons Inc is uncovered by Eyestock quantitative analysis.
Qrons, Inc. is a preclinical stage biotechnology company, which engages in the development of advanced stem cell synthetic hydrogel-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries. The company is headquartered in Long Island City, New York and currently employs 2 full-time employees. The company went IPO on 2017-06-30. The firm is focused on developing biotech products, treatments and technologies to combat neuronal diseases. The company seeks to engage in arrangements with companies and institutions that are developing technologies in the fields of artificial intelligence, machine learning, molecular biology, stem cells and tissue engineering, for deployment in neuronal diseases. The firm has developed two product candidates, QS100TM for treating penetrating brain injuries and QS200TM, for treating concussions and other diffused axonal injuries. Both QS100TM and QS200TM integrate, anti-brain inflammation synthetic hydrogel and modified mesenchymal stem cells (MSCs) and smart synthetic material. Its QS100TM is an injury-specific, three-dimensional (3D) printable, implantable MSCs-synthetic hydrogel to treat penetrating brain injuries and QS200TM is an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries referred to concussions.